282 related articles for article (PubMed ID: 26093347)
41. OPG-Fc but Not Zoledronic Acid Discontinuation Reverses Osteonecrosis of the Jaws (ONJ) in Mice.
de Molon RS; Shimamoto H; Bezouglaia O; Pirih FQ; Dry SM; Kostenuik P; Boyce RW; Dwyer D; Aghaloo TL; Tetradis S
J Bone Miner Res; 2015 Sep; 30(9):1627-40. PubMed ID: 25727550
[TBL] [Abstract][Full Text] [Related]
42. Bacterial promotion of bisphosphonate-induced osteonecrosis in Wistar rats.
Tsurushima H; Kokuryo S; Sakaguchi O; Tanaka J; Tominaga K
Int J Oral Maxillofac Surg; 2013 Nov; 42(11):1481-7. PubMed ID: 23932020
[TBL] [Abstract][Full Text] [Related]
43. Rheumatoid Arthritis Exacerbates the Severity of Osteonecrosis of the Jaws (ONJ) in Mice. A Randomized, Prospective, Controlled Animal Study.
de Molon RS; Hsu C; Bezouglaia O; Dry SM; Pirih FQ; Soundia A; Cunha FQ; Cirelli JA; Aghaloo TL; Tetradis S
J Bone Miner Res; 2016 Aug; 31(8):1596-607. PubMed ID: 26950411
[TBL] [Abstract][Full Text] [Related]
44. Further development of the MRONJ minipig large animal model.
Otto S; Pautke C; Martin Jurado O; Nehrbass D; Stoddart MJ; Ehrenfeld M; Zeiter S
J Craniomaxillofac Surg; 2017 Sep; 45(9):1503-1514. PubMed ID: 28803745
[TBL] [Abstract][Full Text] [Related]
45. Clinical study evaluating the effect of bevacizumab on the severity of zoledronic acid-related osteonecrosis of the jaw in cancer patients.
Lescaille G; Coudert AE; Baaroun V; Ostertag A; Charpentier E; Javelot MJ; Tolédo R; Goudot P; Azérad J; Berdal A; Spano JP; Ruhin B; Descroix V
Bone; 2014 Jan; 58():103-7. PubMed ID: 24120382
[TBL] [Abstract][Full Text] [Related]
46. Comment on: Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients.
Kyrgidis A; Triaridis S
Oral Oncol; 2009 Jun; 45(6):e38; author reply e39. PubMed ID: 19062329
[No Abstract] [Full Text] [Related]
47. High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties.
Pozzi S; Vallet S; Mukherjee S; Cirstea D; Vaghela N; Santo L; Rosen E; Ikeda H; Okawa Y; Kiziltepe T; Schoonmaker J; Xie W; Hideshima T; Weller E; Bouxsein ML; Munshi NC; Anderson KC; Raje N
Clin Cancer Res; 2009 Sep; 15(18):5829-39. PubMed ID: 19737962
[TBL] [Abstract][Full Text] [Related]
48. Chemotherapeutic and antiresorptive combination therapy suppressed lymphangiogenesis and induced osteonecrosis of the jaw-like lesions in mice.
Kuroshima S; Yamashita J
Bone; 2013 Sep; 56(1):101-9. PubMed ID: 23727433
[TBL] [Abstract][Full Text] [Related]
49. Zoledronate induces osteonecrosis of the jaw in sheep.
Voss PJ; Stoddart M; Ziebart T; Zeiter S; Nelson K; Bittermann G; Schmelzeisen R; Poxleitner P
J Craniomaxillofac Surg; 2015 Sep; 43(7):1133-8. PubMed ID: 26154396
[TBL] [Abstract][Full Text] [Related]
50. Bisphosphonate-related osteonecrosis of jaws in 3 osteoporotic patients with history of oral bisphosphonate use treated with single yearly zoledronic acid infusion.
Fitzpatrick SG; Stavropoulos MF; Bowers LM; Neuman AN; Hinkson DW; Green JG; Bhattacharyya I; Cohen DM
J Oral Maxillofac Surg; 2012 Feb; 70(2):325-30. PubMed ID: 21723015
[No Abstract] [Full Text] [Related]
51. Effects of Zoledronic Acid in Experimental Periapical Lesions in Rats: An Imaging and Histological Analysis.
França TRT; Ramos-Perez FMM; Pontual ADA; Castro JFL; Bonan PRF; Perez DEDC
Braz Dent J; 2017; 28(5):566-572. PubMed ID: 29215680
[TBL] [Abstract][Full Text] [Related]
52. Combination of zoledronic Acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma.
Smidt-Hansen T; Folkmar TB; Fode K; Agerbaek M; Donskov F
J Oral Maxillofac Surg; 2013 Sep; 71(9):1532-40. PubMed ID: 23642545
[TBL] [Abstract][Full Text] [Related]
53. The effects of icariin on wound healing of extraction sites with administration of zoledronic and dexamethasone: A rat model study.
Liu J; Mattheos N; Su C; Deng C; Luo N; Wang Z; Tang H
J Oral Pathol Med; 2018 Feb; 47(2):198-205. PubMed ID: 29130610
[TBL] [Abstract][Full Text] [Related]
54. Medication-related osteonecrosis of the jaw using periodontitis-induced rat before tooth extraction.
Park KM; Cheong J; Pang NS; Kim KD; Lee JS; Park W
BMC Oral Health; 2023 Aug; 23(1):561. PubMed ID: 37573298
[TBL] [Abstract][Full Text] [Related]
55. Establishment of an Animal Model of Bisphosphonate-Related Osteonecrosis of the Jaws in Spontaneously Diabetic Torii Rats.
Takaoka K; Yamamura M; Nishioka T; Abe T; Tamaoka J; Segawa E; Shinohara M; Ueda H; Kishimoto H; Urade M
PLoS One; 2015; 10(12):e0144355. PubMed ID: 26659123
[TBL] [Abstract][Full Text] [Related]
56. A novel animal model to study non-spontaneous bisphosphonates osteonecrosis of jaw.
Biasotto M; Chiandussi S; Zacchigna S; Moimas S; Dore F; Pozzato G; Cavalli F; Zanconati F; Contardo L; Giacca M; Di Lenarda R
J Oral Pathol Med; 2010 May; 39(5):390-6. PubMed ID: 20202091
[TBL] [Abstract][Full Text] [Related]
57. Influence of the cumulative effect of zoledronic acid on periodontal microcirculation in rats.
Kosach GA; Petrosyan AL; Yaremenko AI; Kutukova SI; Zubareva AA; Chefu SG; Vlasov TD
Oral Maxillofac Surg; 2021 Dec; 25(4):487-494. PubMed ID: 33586116
[TBL] [Abstract][Full Text] [Related]
58. Medication-related osteonecrosis of the jaw. Introduction of a new modified experimental model.
Curra C; Cardoso CL; Ferreira O; Curi MM; Matsumoto MA; Cavenago BC; Santos PL; Santiago JF
Acta Cir Bras; 2016 May; 31(5):308-13. PubMed ID: 27275851
[TBL] [Abstract][Full Text] [Related]
59. Transient disturbance in physeal morphology is associated with long-term effects of nitrogen-containing bisphosphonates in growing rabbits.
Smith EJ; Little DG; Briody JN; McEvoy A; Smith NC; Eisman JA; Gardiner EM
J Bone Miner Res; 2005 Oct; 20(10):1731-41. PubMed ID: 16160731
[TBL] [Abstract][Full Text] [Related]
60. Effect of zoledronic acid on osseointegration of titanium implants: an experimental study in an ovariectomized rabbit model.
Yildiz A; Esen E; Kürkçü M; Damlar I; Dağlioğlu K; Akova T
J Oral Maxillofac Surg; 2010 Mar; 68(3):515-23. PubMed ID: 20171470
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
